Brentuximab vedotin: An anti-CD30 antibody–drug conjugate

201348 citationsReview

Authors

Amber M. Bradley · University of Georgia

Meghan Devine · Southeast Georgia Health System

David L. DeRemer · University of Georgia

Abstract

Brentuximab vedotin, a novel antibody-drug conjugate combining a cytotoxic agent with a selective monoclonal antibody, is a therapeutic option for patients with relapsed or refractory Hodgkin lymphoma and sALCL. Phase I and II studies have shown brentuximab to have a manageable toxicity profile.

Topics & Keywords

Lymphoma Diagnosis and Treatment Cutaneous lymphoproliferative disorders research CAR-T cell therapy research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: American Journal of Health-System Pharmacy

Volume 70, Issue 7, pp. 589-597

DOI: 10.2146/ajhp110608

Field-Weighted Citation Impact: 3.76